TB-500 and Thymosin Beta-4: Trade Name, Fragment, and What the Research Uses
·5 min read
If you have searched for TB-500, you have encountered a naming problem. The term is used across the research peptide market to refer to at least two chemically distinct things: the full Thymosin Beta-4 peptide, and a shortened fragment of it. Understanding the difference — and why it matters for research — requires going back to what the published literature actually studied.
01 — Thymosin Beta-4: The Source Compound
Thymosin Beta-4 (TB-4) is a naturally occurring 43-amino acid peptide present at high concentrations in virtually all human and mammalian cells. It is one of the most abundant intracellular peptides in the body, with particularly high concentrations in platelets and wound fluid — an early signal of its involvement in tissue repair processes.
Its primary structural role is as an actin-sequestering protein. TB-4 binds G-actin (the monomeric form) and regulates its polymerisation into F-actin (the filamentous form). This control over actin dynamics is central to cell migration, wound closure, and the formation of new blood vessels — which is why TB-4's research profile spans wound healing, angiogenesis, cardiac repair, and neuroprotection.
The compound studied in the published literature is the full 43-amino acid sequence. When Goldstein et al., Kleinman et al., and the broader body of NIH-affiliated TB-4 research refers to Thymosin Beta-4, this is what they are studying.
02 — What "TB-500" Actually Means
TB-500 is not a scientific name. It is a trade name that emerged in the research peptide market, and it is applied inconsistently.
In some cases, "TB-500" refers to the full Thymosin Beta-4 peptide — the complete 43-amino acid sequence, synthetically manufactured and identical to the endogenous compound. In this usage, TB-500 and Thymosin Beta-4 are the same thing under different names.
In other cases — and this is where the problem lies — "TB-500" is used to describe a fragment of Thymosin Beta-4: a shorter peptide derived from the actin-binding domain of the full sequence. This fragment is structurally distinct from full Thymosin Beta-4. It retains part of the actin-sequestering activity but lacks the complete peptide structure and the additional functional regions of the full molecule.
The fragment is cheaper and simpler to synthesise than the full 43-amino acid peptide. This creates a commercial incentive to sell the fragment under the same TB-500 name, at similar prices, without making the distinction clear.
03 — The Fragment vs the Full Peptide: Why It Matters
TB-4's biological activity is not reducible to its actin-binding domain alone. The full peptide contains multiple functional regions. Published research has identified activity related to:
Actin sequestration — regulating the G-actin/F-actin equilibrium, driving cell motility and wound closure
Anti-inflammatory signalling — modulating NF-κB pathway activity and cytokine production in injury models
Angiogenesis — promoting endothelial cell migration and new vessel formation in wound and ischaemia models
Cardiac repair — documented effects in myocardial injury models, including cardiomyocyte survival and cardiac progenitor cell activation
Neuroprotection — studied in CNS injury models for neuronal survival effects
A fragment targeting only the actin-binding domain may replicate part of this activity, but it cannot replicate the full profile of the complete peptide. More critically: the published research that documents this activity was conducted with the full Thymosin Beta-4 sequence. Using a fragment and expecting to reproduce published full-TB4 findings is a category error — the compound is different, and the research basis for expected outcomes does not transfer.
For research designed to reproduce or build on the published Thymosin Beta-4 literature, the full 43-amino acid peptide is the only appropriate form.
04 — Why We Sell TB-4, Not TB-500
Dubai Peptides lists this compound under its scientific name — Thymosin Beta-4 (TB-4) — rather than the trade name TB-500. This is intentional: the TB-500 designation is ambiguous, and ambiguity about what a research compound actually is represents a quality and reproducibility problem.
What we supply is the full 43-amino acid Thymosin Beta-4 sequence, synthesised to ≥99% HPLC purity and verified by mass spectrometry. This is the form used in the published research, and it is the form required for research that intends to engage with that literature.
If you are sourcing TB-500 from a supplier who does not clearly specify whether they are supplying the full peptide or a fragment, that is worth resolving before use.
